Article
Public, Environmental & Occupational Health
Matthew S. Painschab, Racquel Kohler, Stephen Kimani, Wilberforce Mhango, Bongani Kaimila, Takondwa Zuze, Victor Mithi, Edwards Kasonkanji, Noel Mumba, Richard Nyasosela, Stephanie Wheeler, Satish Gopal
Summary: The study evaluated the cost-effectiveness of DLBCL treatment in Malawi, demonstrating that CHOP is cost-effective at the patient level, and the addition of rituximab may also be cost-effective.
LANCET GLOBAL HEALTH
(2021)
Article
Medicine, Research & Experimental
Yuqin Song, Hui Zhou, Huilai Zhang, Wei Liu, Yuerong Shuang, Keshu Zhou, Fangfang Lv, Hao Xu, Jianfeng Zhou, Wei Li, Huaqing Wang, Hongyu Zhang, Haiwen Huang, Qingyuan Zhang, Wei Xu, Zheng Ge, Ying Xiang, Shuye Wang, Da Gao, Shun'e Yang, Jinying Lin, Lin Wang, Liqun Zou, Meifang Zheng, Jing Liu, Zonghong Shao, Ying Pang, Ruixiang Xia, Zhendong Chen, Ming Hou, Hongxia Yao, Ru Feng, Zhen Cai, Mingzhi Zhang, Wenhua Ran, Lin Liu, Shan Zeng, Wei Yang, Peng Liu, Aibin Liang, Xuelan Zuo, Qingfeng Zou, Junxun Ma, Wei Sang, Ye Guo, Wei Zhang, Yongqing Cao, Yan Li, Jifeng Feng, Xin Du, Xiaohong Zhang, Hongguo Zhao, Hui Zhou, Jie Yu, Xing Sun, Jun Zhu, Lugui Qiu
Summary: The study demonstrated that IBI301 and rituximab showed similar efficacy and safety in previously untreated DLBCL patients, indicating that IBI301 plus CHOP could be a potential treatment regimen for this patient population.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, Brigitte Laguerre, Stephane Oudard, Marine Gross-Goupil, Gwenaelle Gravis, Francois Goldwasser, Frederic Rolland, Remy Delva, Laura Moise, Sheik Emambux, Cecile Vassal, Sylvie Zanetta, Nicolas Penel, Aude Flechon, Philippe Barthelemy, Carolina Saldana, Felix Lefort, Bernard Escudier, Claude Linassier, Laurence Albiges
Summary: The study showed that sunitinib and everolimus had similar efficacy in first-line treatment of patients with mpRCC, with no significant differences in PFS, DCR, PFS-2, and OS between the two treatment groups. Prognostic factors for OS included leukocytosis, anaemia, and the time from diagnosis to first systemic therapy, while there was no prognostic difference between pRCC subtypes.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Hematology
Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
Summary: The dilemma of using full or reduced dose intensity of R-CHOP in elderly patients with DLBCL was studied through a systematic review. Lower dose intensity was associated with poorer survival outcomes in most studies, especially in patients aged <80 years. However, elderly patients aged >= 80 years did not show consistent impact on survival outcomes with reduced dose intensity, suggesting full-dose R-CHOP may be more appropriate in this age group. Additional DI-specific randomized trials are needed for further confirmation.
Letter
Oncology
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi, Masahito Shimizu
Summary: This study aimed to evaluate the efficacy and safety of BRAC combination therapy in patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma. The results showed that BRAC therapy had a good response rate but also caused significant hematological toxicity.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Hailing Liu, Xiao Shi, Huizi Fang, Lei Cao, Yi Miao, Xiaoli Zhao, Wei Wu, Wei Xu, Jianyong Li, Lei Fan
Summary: This study systematically reviewed the use of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) and found that the benefit of ASCT has been weakened in the era of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HiDAC) treatment. Alternative first-line maintenance strategies should be explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jun Ho Yi, Seok Jin Kim, Jeong-ok Lee, Gyeong-won Lee, Jae-yong Kwak, Hyeon-seok Eom, Jae-cheol Jo, Yoon Seok Choi, Sung Yong Oh, Won Seog Kim
Summary: The combination of bendamustine and rituximab (BR) is highly effective for the treatment of mantle cell lymphoma (MCL) in Korean patients, both as first-line treatment and salvage treatment. BR treatment shows favorable progression-free survival and overall survival rates.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Theodoros P. Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, Georgia Kourti, Maria K. Angelopoulou, Fotios Panitsas, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Evangelos Terpos, Maria N. Dimopoulou, Stamatios Karakatsanis, Eurydiki Michalis, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Theophanis Economopoulos, Lydia Kyriazopoulou, Marina P. Siakantaris, Marie-Christine Kyrtsonis, Argyris Symeonidis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Hatjiharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Gabriella Gainaru, Ekaterini Stefanoudaki, Panayiotis Zikos, Panayiotis Tsirigotis, Gerasimos Tsourouflis, Theodora Assimakopoulou, Pavlina Konstantinidou, Helen A. Papadaki, Katerina Megalakaki, Meletios-Athanasios Dimopoulos, Vassiliki Pappa, Themis Karmiris, Paraskevi Roussou, Panayiotis Panayiotidis, Kostas Konstantopoulos, Gerassimos A. Pangalis
Summary: Clinical prognostic factors play a significant role in predicting the outcome of patients with PMLBCL treated with R-CHOP, with two models performing better than established risk scores. These models can help in identifying high-risk subgroups and determining the need for more intensive treatment.
Article
Oncology
Rouslan Kotchetkov, Ian R. Drennan, David Susman, Erica DiMaria, Lauren Gerard, Derek Nay, Anca Prica
Summary: This study compared the safety and efficacy of BR therapy in elderly and younger patients. The results showed that elderly patients were more likely to experience treatment delays and dose reductions, but the disease control outcome was similar between the two groups.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Roberto Castelli, Antonio Gidaro, Giorgio L. Deliliers, Luigi Bergamaschini
Summary: R-CHOP is the standard treatment for DLBCL patients, but bendamustine and rituximab has shown promising results in elderly frail patients. The study demonstrated high response rates and acceptable toxicity with bendamustine and rituximab, suggesting it as a reasonable alternative for elderly DLBCL patients.
Review
Oncology
Radhika Takiar, Tycel Phillips
Summary: Mantle cell lymphoma is a rare and incurable non-Hodgkin lymphoma with heterogeneous clinical presentation. Current frontline treatment approaches may increase toxicities without providing a cure, leading researchers to explore genomic profiling for potential targeted therapies in the future. Non-chemotherapy options may become more favored for frontline therapy over conventional chemotherapy and stem cell transplants based on the discussed data.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Dermatology
Ji Yun Lee, Minsu Kang, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee, Jeong-Ok Lee
Summary: This study found that PCP prophylaxis is highly effective in preventing PCP infection in DLBCL patients undergoing R-CHOP treatment, which can guide prevention strategies for PCP.
Article
Oncology
Zola Musimar, Mtonga Mpetani, Jeremy S. Abramson, Bruce A. Chabner, Zainab Mohamed
Summary: This retrospective cohort study found that treatment of DLBCL with R-CHOP, including rituximab, can achieve good outcomes in resource-limited settings. In this HIV-negative patient cohort, poor performance status was the most important adverse prognostic factor.
Article
Oncology
Andrew J. Davies, Sharon Barrans, Louise Stanton, Josh Caddy, Sam Wilding, Geoff Saunders, Christoph Mamot, Urban Novak, Andrew McMillan, Paul Fields, Graham P. Collins, Richard Stephens, Francesco Cucco, Chulin L. Sha, Moniek van Hoppe, Reuben Tooze, John R. Davies, Gareth Griffiths, Anna Schuh, Catherine Burton, David R. Westhead, Ming-Qing Du, Peter W. M. Johnson
Summary: Clinical trials often have multiple end points that mature at different times. The initial report may be published before all planned co-primary or secondary analyses are available. Clinical Trial Updates provide an opportunity to publish additional results from studies for which the primary end point has already been reported. The REMoDL-B phase III adaptive trial compared different chemotherapy regimens in patients with DLBCL, and the updated analysis showed that patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Hematology
David Sermer, Pavania Elavalakanar, Jeremy S. Abramson, M. Lia Palomba, Gilles Salles, Jon Arnason
Summary: CD19 is widely present on B-lymphocytes and B-cell malignancies. CD19-directed CAR T cells have improved outcomes in B-cell malignancies, but there are limitations. CD19 can also be targeted by other drugs, but optimal patient selection and sequencing are not established. This review focuses on CD19 as a target for DLBCL treatment, discussing clinical trials of tafasitamab, loncastuximab tesirine, and blinatumo-mab, and the potential of re-challenging with anti-CD19 therapies post-CAR T cells.
Article
Oncology
Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, Rene-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Krimo Bouabdallah, Pierre Feugier, Lena Specht, Lysiane Molina, Mohamed Touati, Cecile Borel, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Laurent Pascal, Pieternella Lugtenburg, Nicola Di Renzo, Thierry Vander Borght, Alexandra Traverse-Glehen, Peggy Dartigues, Martin Hutchings, Annibale Versari, Michel Meignan, Massimo Federico, Marc Andre
Summary: This study evaluated the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in early-stage unfavorable Hodgkin lymphoma. The results showed that BV-AVD had a higher PET-negative rate compared to ABVD after two cycles. High total metabolic tumor volume was associated with shorter progression-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Peter Martin, Jonathon B. Cohen, Michael Wang, Anita Kumar, Brian Hill, Diego Villa, Jeffrey M. Switchenko, Brad Kahl, Kami Maddocks, Natalie S. Grover, Keqin Qi, Lori Parisi, Katherine Daly, Angeline Zhu, Gilles Salles
Summary: This study analyzed the data of 4,216 patients with mantle cell lymphoma and found that only one in four young patients received high-dose cytarabine-based induction and autologous stem-cell transplant (ASCT) consolidation in the US community setting, indicating the need for effective treatments in routine clinical practice. Additionally, maintenance rituximab (MR) after bendamustine plus rituximab (BR) was associated with longer time to next treatment and overall survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fabien Ricard, Sally Barrington, Ron Korn, Guenther Brueggenwerth, Judith Trotman, Bruce Cheson, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Annette Schmid
Summary: The aim of this initiative was to provide consensus recommendations for the consistent application of imaging assessment with the Lugano classification in the field of lymphoma and imaging. Consensus was obtained through a series of sponsored meetings, resulting in recommendations to clarify technical considerations and provide guidance on the role of imaging and clinical reviewers in the classification. An example template of an imaging case report form is also provided to support efficient data collection. These consensus recommendations address technical and imaging areas of inconsistency and ambiguity in the classification encountered by end users.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn
Summary: This article presents consensus recommendations on the consistent application of the Lugano classification in the field of lymphoma and imaging. The recommendations were obtained through meetings involving academic and industry experts and provide updates and clarifications on the technical considerations and scoring guidelines of the Lugano classification. These consensus recommendations aim to address inconsistencies and ambiguities encountered by end users during response evaluation and should be used alongside the 2014 Lugano classification as a companion guide.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Hematology
Lorenzo Falchi, Santosha A. Vardhana, Gilles A. Salles
Summary: Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have undergone significant changes in the past two decades due to the introduction of highly active immunotherapies. Bispecific antibodies (BsAb) have emerged as a promising immunotherapeutic for B-NHL, with anti-CD20xCD3 BsAb showing remarkable single-agent activity. However, further research is needed to determine the optimal deployment of these drugs, ideal combination partners, strategies for minimizing toxicity, and pharmacodynamic biomarkers of response and resistance.
Review
Hematology
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
Caroline Algrin, Louis Perol, Elise Chapiro, Lucile Baseggio, Karim Maloum, Catherine Settegrana, Jean-Francois Lesesve, Justine Siavellis, Alain Delmer, Anne-Sophie Michallet, Emmanuelle Ferrant, Pierre Feugier, Cecile Tomowiak, Annie Brion, David Ghez, Luc-Matthieu Fornecker, Sarah Ivanoff, Stephanie Struski, Laurent Sutton, Isabelle Radford-Weiss, Virginie Eclache, Christine Lefebvre, Veronique Leblond, Florence Nguyen-Khac, Damien Roos-Weil, Innovative Leukemia Org
Article
Multidisciplinary Sciences
Julien Broseus, Sebastien Hergalant, Julia Vogt, Eugen Tausch, Markus Kreuz, Anja Mottok, Christof Schneider, Caroline Dartigeas, Damien Roos-Weil, Anne Quinquenel, Charline Moulin, German Ott, Odile Blanchet, Cecile Tomowiak, Gregory H. Lazarian, Pierre Rouyer, Emil Chteinberg, Stephan Bernhart, Olivier Tournilhac, Guillaume Gauchotte, Sandra Lomazzi, Elise Chapiro, Florence Nguyen-Khac, Celine Chery, Frederic Davi, Mathilde Hunault, Remi Houlgatte, Andreas Rosenwald, Alain Delmer, David Meyre, Marie-Christine Bene, Catherine Thieblemont, Peter Lichter, Ole Ammerpohl, Jean-Louis Gueant, Romain Guieze, Jose Ignacio Martin-Subero, Florence Cymbalista, Pierre Feugier, Reiner Siebert, Stephan Stilgenbauer
Summary: This study characterizes the DNA methylation and transcriptomic profiles of Richter syndrome (RS), and develops classifiers for RS-type de novo diffuse large B-cell lymphomas (DLBCLs).
NATURE COMMUNICATIONS
(2023)
Article
Hematology
Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schoeder, Heather Jacene
Summary: This study found that interim PET scans after 2-4 cycles of frontline chemoimmunotherapy can predict progression-free survival in follicular lymphoma patients, and may be used as a tool for response-adapted treatment strategies.
Article
Oncology
Dipti Talaulikar, Cecile Tomowiak, Elise Toussaint, Pierre Morel, Prashant Kapoor, Jorge J. Castillo, Alain Delmer, Eric Durot
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2023)
Article
Oncology
Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A. Hamlin, Steven Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, M. Lia Palomba, David J. Straus, Gottfried Von Keudell, Lorenzo Falchi, Joachim Yahalom, Andrew D. Zelenetz, Anas Younes, Gilles Salles, Heiko Schoeder, Erel Joffe
Summary: This study discusses the limitations of using interim PET for decision-making and prognosis in the frontline management of Hodgkin's lymphoma. It presents data suggesting that patients who continue treatment with ABVD despite not achieving a complete metabolic response on interim PET may have better outcomes than previously thought. The study also compares the performance of different methods for evaluating PET positivity. Overall, the results indicate that a subset of patients can continue ABVD treatment without a poor outcome, regardless of the criteria for PET2 positivity.
Article
Hematology
Anne-Sophie Michallet, Remi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Veronique Leblond, Cecile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Therese Aurran Schleinitz, Florence Cymbalista, Stephane Lepretre, Vincent Levy, Florence Nguyen-Khac
Summary: In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), a fixed-duration immunochemotherapy approach yielded deep and sustained peripheral blood measurable residual disease (MRD) responses, high survival rates, and low long-term toxicity. A randomized trial is needed to compare this approach with a chemotherapy-free strategy. The ICLL-07 trial demonstrated promising results with 4-year progression-free and overall survival rates of 95.5% and 96.2%, respectively.
Article
Oncology
Marie Balsat, Vincent Alcazer, Gabriel Etienne, Francoise Huguet, Marc Berger, Emilie Cayssials, Aude Charbonnier, Martine Escoffre-Barbe, Hyacinthe Johnson-Ansah, Laurence Legros, Lydia Roy, Alain Delmer, Jean-Christophe Ianotto, Corentin Orvain, Fabrice Larosa, Mathieu Meunier, Shanti Ame, Annalisa Andreoli, Pascale Cony-Makhoul, Stephane Morisset, Isabelle Tigaud, Delphine Rea, Franck Emmanuel Nicolini
Summary: This retrospective study observed the clinical data of newly diagnosed accelerated phase chronic myeloid leukemia (AP-CML) patients who received second-generation tyrosine kinase inhibitors (TKI2) as first-line treatment. The results showed that TKI2 could effectively improve the survival and treatment response of patients.
Article
Medicine, General & Internal
Carole Durot, Eric Durot, Sebastien Mule, David Morland, Francois Godard, Anne Quinquenel, Alain Delmer, Philippe Soyer, Christine Hoeffel
Summary: The purpose of this study was to determine whether texture features on pretreatment unenhanced CT images derived from 18F-FDG PET/CT can predict survival outcomes in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. The study found that skewness at a fine texture scale and kurtosis without filtration were independent predictors of progression-free survival and time to next treatment. The results suggest that pretreatment unenhanced CT texture analysis-derived skewness and kurtosis can be used as predictive biomarkers for survival outcomes in patients with high-tumor-burden follicular lymphoma.
